Drugs that contain Aclidinium Bromide
1. Tudorza Pressair patents expiration
TUDORZA PRESSAIR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7078412 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(3 years ago) | |
| US6750226 | COVIS | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands |
Sep, 2020
(3 years ago) | |
| USRE46417 | COVIS | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands |
Feb, 2025
(9 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6071498 | COVIS | Inhaler for powdered medicaments |
Jun, 2016
(7 years ago) | |
| US5840279 | COVIS | Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments |
Jun, 2016
(7 years ago) | |
| US9056100 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(3 years ago) | |
| US10588895 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(3 years ago) | |
| US9333195 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(3 years ago) | |
| US10034867 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(3 years ago) | |
| US6681768 | COVIS | Powder formulation disintegrating system and method for dry powder inhalers |
Aug, 2022
(1 year, 8 months ago) | |
| US8051851 | COVIS | Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler |
Apr, 2027
(3 years from now) | |
| US10085974 | COVIS | Dosage and formulation |
Mar, 2029
(4 years from now) | |
| US11000517 | COVIS | Dosage and formulation |
Mar, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-256) | Mar 29, 2022 |
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2017 |
NCE-1 date: 23 July, 2016
Market Authorisation Date: 23 July, 2012
Treatment: Maintenance treatment of chronic obstructive pulmonary disease (copd); Maintenance treatment of chronic pulmonary disease (copd); Maintenance treatment of bronchospasm associated with chronic obstruct...
Dosage: POWDER, METERED;INHALATION
More Information on Dosage
TUDORZA PRESSAIR family patents
